Incidence of Immune-Related Adverse Events with Program Death Receptor-1- and Program Death Receptor-1 Ligand-Directed Therapies in Genitourinary Cancers
about
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.Development of shellfish allergy after exposure to dual immune checkpoint blockadeImaging Response of Antiangiogenic and Immune-Oncology Drugs in Metastatic Renal Cell Carcinoma (mRCC): Current Status and Future Challenges
P2860
Incidence of Immune-Related Adverse Events with Program Death Receptor-1- and Program Death Receptor-1 Ligand-Directed Therapies in Genitourinary Cancers
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Incidence of Immune-Related Ad ...... apies in Genitourinary Cancers
@en
Incidence of Immune-Related Ad ...... pies in Genitourinary Cancers.
@nl
type
label
Incidence of Immune-Related Ad ...... apies in Genitourinary Cancers
@en
Incidence of Immune-Related Ad ...... pies in Genitourinary Cancers.
@nl
prefLabel
Incidence of Immune-Related Ad ...... apies in Genitourinary Cancers
@en
Incidence of Immune-Related Ad ...... pies in Genitourinary Cancers.
@nl
P2093
P2860
P356
P1476
Incidence of Immune-Related Ad ...... apies in Genitourinary Cancers
@en
P2093
Benjamin L Maughan
David M Gill
Erin Bailey
Neeraj Agarwal
P2860
P356
10.3389/FONC.2017.00056
P577
2017-04-03T00:00:00Z